Popular Articles

Advaxis Engages The Numoda Corporation To Oversee Phase II Clinical Trials Of ADXS11-001
Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia).
generic viagra
L.A. County, Calif., Offers Home Delivery Of Chlamydia, Gonorrhea Test Kits
Los Angeles County health officials on Wednesday announced a program that will offer young women home delivery of chlamydia and gonorrhea testing kits and send them a text message when the results are available, the AP/San Francisco Chronicle reports. The $450,000 program aims to curb the rapid spread of sexually transmitted infections in the county while also reducing clinic wait times and costs.According to Centers for Disease Control and Prevention statistics, Los Angeles County in 2007 led the nation in reported chlamydia cases with 44,030 and ranked second for reported gonorrhea cases with 10,063. CDC has labeled chlamydia a hidden epidemic because women often display no symptoms. It is estimated that three million men and women contract the infection annually. Although chlamydia is treatable with antibiotics, women with untreated cases can experience infertility, higher risk for ectopic pregnancy and other problems. Peter Kerndt, director of the county"s STI program, said that the number of reported cases is expected to rise after the program"s implementation. According to county Health Director Jonathan Fielding, more than 50% of reported cases involve women younger than age 25, many of whom are black and Hispanic teens. It is recommended that women younger than age 25 receive annual testing.Under the program, 10,000 chlamydia and gonorrhea testing kits will be immediately available, with more offered as needed, according to county Supervisor Zev Yaroslavsky. To request a kit, women can visit a Web site or call a toll-free number to have the kits mailed to them. Women can administer the tests at home by inserting a vaginal swab for 10 seconds, sealing the swab in a plastic tube and mailing it to the testing center. They can opt to have a text message sent to their phone alerting them when their results are ready, which can be checked by phone or online. Women will then be referred to a local health clinic if needed. Similar programs have been implemented in Denver, Maryland, Washington, D.C., West Virginia and some Illinois counties. The Los Angeles County program is modeled on a Baltimore pilot program led by the Johns Hopkins School of Medicine (Mohajer, AP/San Francisco Chronicle, 6/11).
News of the day
Sciele Pharma And Plethora Solutions Announce Positive Results Of Final Phase III Pivotal Trial For PSD502 For Premature Ejaculation
Sciele Pharma Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE), announced that a second and final Phase III double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation ("PE") has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time ("IELT"), Index of Premature Ejaculation ("IPE," Ejaculatory Control, Sexual Satisfaction and Distress domains).
Diagnostics

Identifying Pathways In The Brain To Understand The Underlying Molecular Mechanism Of Huntington's Disease

Florida Atlantic University researcher Dr. Jianning Wei, assistant professor of biomedical sciences in the Charles E. Schmidt College of Biomedical Science at FAU, has received a grant from the National Institutes of Health (NIH) to further her research into the molecular mechanisms of Huntington"s disease (HD). Named after American physician George Huntington, HD is a highly complex genetic, neurological disorder that causes certain nerve cells in the brain to waste away. The disease, characterized by a selective loss of neurons in the brain, affects the basal ganglia, which controls motor control, cognition, learning and emotions. It also affects the outer surface of the brain, or the cortex which controls thought, perception, and memory. Wei and her colleagues are working to identify the pathways in the brain that are altered in response to mutant proteins, as well as to understand the cellular processes impacted by the disease in order to facilitate the development of effective pharmacological interventions. HD is a fatal, inherited disease caused by abnormal repeats of a small segment in an individual"s DNA, or genetic code. The production of malfunctioning proteins in the body are results of these mutations, and the more it is repeated, the worse the disease. A person who has the disease carries one normal copy of the gene and one mutated copy in his or her cells. These abnormal repeats also are involved in several other neurodegenerative diseases. Although the mutated forms of these genes are known for their devastating effects, their normal forms are critical for nerve function, embryonic development and other bodily processes. "The underlying molecular mechanism of HD remains elusive," said Wei. "We hope that the information we obtain from our studies will improve the current understanding of the molecular pathways that are altered in response to mutant huntingtin or mHtt." Wei"s findings may also represent a universal mechanism in the pathogenesis of neurodegenerative diseases that are involved with protein misfolding and aggregation (a phenomenon that occurs in many highly debilitating disorders including neurodegenerative diseases). Preliminary data from their findings using an in vitro cell model of HD suggest that there is a novel mechanism for mHtt induced cell death, or apoptosis. Apoptosis has been proposed as one of the mechanisms leading to neuronal death in HD. With this NIH grant, Wei and her colleagues will be testing their hypothesis in a mouse model of HD. Although recent studies provide important clues, precisely how mHtt triggers apoptosis still remains unclear. HD can be traced back as far as the Middle Ages and one of the earlier names for the disease was "chorea" as in "choreography" and is the Greek word for dance, describing how people affected with the disorder constantly twist and turn in an uncontrollable dance-like motion. People are born with the single defective gene that produces HD and symptoms don"t appear until middle age. In addition to uncontrolled movements, neurological degeneration also causes loss of intellectual faculties and emotional disturbance. As the disease progresses, HD can affect a person"s ability to walk, talk and swallow. Today, approximately 30,000 Americans are living with HD. In addition, a staggering 200,000 more are at risk. Although physicians may prescribe a number of medications to help control emotional and movement problems associated with HD, there is no treatment to stop or reverse the course of the disease. Current investigation of HD includes clinical research, basic neurobiology, imaging, fetal tissue research and animal models of the disease. Florida Atlantic University opened its doors in 1964 as the fifth public university in Florida. Today, the University serves more than 26,000 undergraduate and graduate students on seven campuses strategically located along 150 miles of Florida"s southeastern coastline. Building on its rich tradition as a teaching university, with a world-class faculty, FAU hosts ten colleges: College of Architecture, Urban & Public Affairs, Dorothy F. Schmidt College of Arts & Letters, the Charles E. Schmidt College of Biomedical Science, the Barry Kaye College of Business, the College of Education, the College of Engineering & Computer Science, the Harriet L. Wilkes Honors College, the Graduate College, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. Florida Atlantic University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):